Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

India's Biotech Department Steps In To Boost Biosimilars Programs Of Indian Companies

This article was originally published in PharmAsia News

Executive Summary

MUMBAI - Realizing the importance of developing inexpensive biotech treatments, India's Department of Biotechnology has for the first time invited proposals from Indian companies to work together on the development of biosimilar products

You may also be interested in...



Lack Of Risk Funding Impedes India's Discovery R&D Growth But Mindset Change Is Making A Difference, Report Says

MUMBAI - Acute shortage of risk funding is turning to be a significant impediment for development of innovative companies in India, especially for start-ups looking to scale their operations or invest in new R&D technologies, the latest report titled Financing Ecosystem of the Indian Life Science Industry by investment bank Yes Bank and industry lobby Confederation of Indian Industry noted

Lack Of Risk Funding Impedes India's Discovery R&D Growth But Mindset Change Is Making A Difference, Report Says

MUMBAI - Acute shortage of risk funding is turning to be a significant impediment for development of innovative companies in India, especially for start-ups looking to scale their operations or invest in new R&D technologies, the latest report titled Financing Ecosystem of the Indian Life Science Industry by investment bank Yes Bank and industry lobby Confederation of Indian Industry noted

Launch Delays In U.S. Dampen Dr. Reddy's Q1 Earnings But Money Starts Flowing From GSK Deal; Analysts Confident On Future Outlook

MUMBAI - The first tangible benefits of the deal Dr. Reddy's Labs struck last year with GlaxoSmithKline for supply of over 100 branded formulations have become visible with the Indian company receiving $4 million from its British partner in return for moving dossiers and trademarks for nine currently marketed products in Brazil

UsernamePublicRestriction

Register

LL1123738

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel